PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy

Table 1 Correlations of PTPRO methylation with different clinicopathological parameters

	Total no.	PTPRO methylated		PTPRO unmethylated		χ²	P-value
	Total no.	NO	%	NO	%	χ²	P-value
All	175	130	74.3	45	25.7
Age at diagnosis, years
<45	56	46	82.1	10	17.9	2.662	0.103
> = 45	119	84	70.6	35	29.4
pT
0-1	12	7	58.3	5	41.7	3.885	0.146
2	118	93	78.8	25	21.2
3-4	40	27	67.5	13	32.5
NA	5	3		2
pN
0	74	51	68.9	23	31.1	7.75	0.051
1	41	27	65.9	14	34.1
2	43	37	86.0	6	14.0
3	16	14	87.5	2	12.5
NA	3	2		1
Clinical stage
I + II	95	68	71.6	27	28.4	1.325	0.25
III	77	61	79.2	16	20.8
NA	3	1		2
Tumor grade
G1 + G2	105	72	68.6	33	31.4	4.481	0.028
G3	67	56	83.6	11	16.4
NA	3	2		1
Estrogen receptor
negative	53	43	81.1	10	18.9	2.432	0.119
positive	105	73	69.5	32	30.5
NA	17	14		3
Progesterone receptor
negative	84	66	78.6	18	21.4	2.448	0.118
positive	74	50	67.6	24	32.4
NA	17	14		3
HER2
negative	80	59	73.8	21	26.3	0.009	0.924
positive	78	57	73.1	21	26.9
NA	17	14		3
Menopausal status
premenopausal	94	75	79.8	19	20.2	2.376	0.123
postmenopausal	79	55	69.6	24	30.4
NA	2	0		2

ISSN: 1479-5876